Stockhub

Allakos Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 September 2022

  • curprev 18:1918:19, 27 September 2022‎ 94.119.64.77 talk‎ 948 bytes +948‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis;..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Allakos_Inc.’